nuBioAge, nuHx and Marius Pharmaceuticals Collaborate on GLP-1 Study in Men

WEST PALM BEACH, Fla., Sept. 25, 2024 /PRNewswire/ -- nuBioAge, a wellness network focused on longevity, headquartered in West Palm Beach, has entered into a collaboration with Marius Pharmaceuticals, maker of the FDA-approved oral testosterone treatment KYZATREX® (testosterone undecanoate) CIII capsules. This alliance involves nuBioAge's new comprehensive assessment and research division, nuHx. The key objective is to initiate a groundbreaking study examining the effects of GLP-1s on muscle mass in men treated for weight loss.

GLP-1 therapies are known to cause muscle mass reduction, decreased energy levels, and overall strength in men undergoing this weight loss treatment. Despite these documented side effects, there is no current treatment available to support men in maintaining muscle mass and energy. The partnership between nuHx and Marius Pharmaceuticals seeks to establish the cause-and-effect relationship between GLP-1s and muscle reduction, and develop a unique treatment that utilizes testosterone to mitigate these effects and encourage muscle growth during weight loss.

Marius Pharmaceuticals will provide KYZATREX for this study, while nuBioAge and nuHx will handle the study assembly and ongoing patient assessments. Patients will receive their medication through Progress Pharmacy, with the study design and data analytics supported by Palm Beach Atlantic University's School of Pharmacy. Bryan Gard, PA-C, head of Gard Wellness Solutions, will oversee patient care as the lead specialist in Hormone Replacement Therapy (HRT) and weight loss.

The study's purpose is to evaluate the combined effect of GLP-1 therapy and KYZATREX® on muscle mass and energy levels in male patients undergoing weight loss. Key metrics such as muscle mass retention, testosterone levels, and VO2 max will be assessed using advanced biomarker tools like PNOE, Dexascan, and various lab-based methods. nuHx's extensive health assessment capabilities provide an ideal setting to monitor these effects.

"GLP-1s are revolutionary in treating obesity and metabolic disorders," said Franck Kacou, PharmD, co-owner of nuBioAge and Head Pharmacist at Progress Pharmacy. "We can enhance the benefits of weight loss by improving BMI and body composition in male patients, helping them maintain muscle mass, strength, and energy levels through proper biomarker monitoring and TRT. This approach can improve a patient's healthspan, quality of life, and longevity."

Recent studies underscore the connection between GLP-1s and muscle loss. Results indicated that individuals taking Semaglutide lost an average of 60% fat and 39% muscle mass, while those on Tirzapetide lost approximately 25% muscle and 75% fat. Lower levels of skeletal muscle mass and physical strength performance have been linked to higher risks of cardiovascular disease and mortality. Testosterone has been shown to aid in muscle mass retention and growth through protein synthesis, making it a potential treatment for muscle loss in male GLP-1 patients.

"This collaboration represents a promising intersection of weight loss and testosterone therapy," stated Shalin Shah, CEO of Marius Pharmaceuticals. "By combining the benefits of GLP-1s with the muscle-building potential of testosterone, we can offer a comprehensive approach to men's health. Our goal is to ensure men not only achieve weight loss but also maintain the strength and energy needed for a healthy life."

The study will commence in December 2024 at the nuHx headquarters in West Palm Beach and is expected to conclude in May 2025. The results will be published following the study's completion. nuBioAge and its partner network remain committed to pioneering unique studies that advance physician education and knowledge in longevity treatment.

About nuBioAge
nuBioAge is a network dedicated to longevity science and wellness education, serving medical practitioners and allied health professionals. It provides an advanced ecosystem of resources, including pharmacy networks, state-of-the-art assessments, and leading longevity research to empower practitioners in delivering patient-centric, evidence-based longevity medicine.

About nuHx
nuHx focuses on comprehensive health assessments through advanced biomarker testing and reporting. It aids physicians in developing personalized patient treatment plans based on a holistic health analysis, aiming to improve healthspan and longevity through preventative treatment.

About Progress Pharmacy
Progress Pharmacy offers personalized clinical care in West Palm Beach, Florida, focusing on natural health, wellness alternatives, and pharmacology solutions. The pharmacy collaborates with research partners to develop customized compounds and therapies to best serve their patients.

About Marius Pharmaceuticals
Marius Pharmaceuticals aims to enhance patients' lives with therapies designed for hypogonadism or Testosterone Deficiency. The company strives to improve metabolic health and reduce unnecessary healthcare costs globally.

About KYZATREX® (testosterone undecanoate)
KYZATREX® is an oral testosterone treatment absorbed primarily via the lymphatic system. It is intended for adult males with conditions related to low or no testosterone levels. The safety and efficacy of KYZATREX® have been demonstrated in clinical studies involving hypogonadal males.